J&J's 2025 drug sales forecast should not be tripping up investors. There's so much else like

Johnson & Johnson (JNJ) reports a strong first quarter, with sales up more than 5.5% and earnings eking out an annual increase.

Konoly Konoly
Apr 19, 2023 - 21:06
0 16
J&J's 2025 drug sales forecast should not be tripping up investors. There's so much else like

A logo sits on a wall inside Johnson & Johnson's innovation centre in London, U.K., on Thursday, July 18, 2013.

Simon Dawson | Bloomberg | Getty Images

Johnson & Johnson (JNJ) before-the-bell Tuesday reported a strong first quarter, with sales up more than 5.5% and earnings eking out an annual increase.

Shares of the Dow component and Club holding should not be losing 2.5% on these kinds of results.